30 closest matches · ranked by relevance
Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Primary: Overall Response Rate — 5; 2; 3; 1 Participants
Leukemia, Acute Myeloid (AML)
Primary: Duration of Overall Survival (OS) — 9.3; 5.6 Months — p=0.0004
Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Primary: Response Rate of Patients Receiving Crenolanib Therapy — 8; 3; 4; 1 Participants
Acute Myeloid Leukemia
Primary: Proportion of Participants With Relapse Free Survival (RFS) up to 18 Months Post Transplant (Full Analysis Set) by Kaplan-Meier Analysis — 0.93; 0.93; 0.80; 0.93…
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants
Leukemia, Myeloid, Acute
Primary: Number of Participants Who Achieved Composite Complete Response (CRc) (Intent-to-Treat Population) — 18; 18 Participants
Leukemia, Myeloid, Acute
Primary: Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML — 56.5; 33.3; 53.8…
Acute Myeloid Leukemia · Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory…
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Primary: Participants With a Response — 3 Participants
Acute Myeloid Leukemia
Primary: Response Rate of Crenolanib Besylate Combination Therapy — 2; 0; 3; 1 Participants
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Primary: Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication — 24.02; 15.84 Months — p=0.163
Leukemia
Primary: Participants With a Response CR + PR + CRi — 4; 1; 4 Participants
Acute Myeloid Leukemia
Primary: Percentage of Patients With Adverse Events (AEs), Grade 3 & 4 AEs, Serious Adverse Events (SAEs), AEs Leading to Discontinuation, and Deaths up to 24 Months (M24)…
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 2 Participants
Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — NA; NA months — p=0.0518
Acute Myeloid Leukemia
Primary: Percentage of Safety Events (Part 1, Japan Only) — 5; 0 Participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
Acute Myeloid Leukemia (AML)
Primary: Event Free Survival (EFS) — 5.98; 5.88 Months
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Number of Participants With a Response of CR, CRp, or PR — 0; 1; 0 participants
Acute Myeloid Leukemia
Primary: Number of Patients Who Relapsed — 5; 2; 0; 1 Participants
Recurrent Acute Myeloid Leukemia · Recurrent Chronic Myelomonocytic Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Participants With a Response — 2; 2 Participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
FLT3 Gene Mutation Negative · FLT3 Internal Tandem Duplication Positive · Recurrent Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of Quizartinib (Phase I) — 60; 60 Milligrams
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Primary: Clinical Response to Crenolanib With Standard Salvage Chemotherapy — 7; 3; 4; 0 Participants
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
Relapsed/Refractory Acute Myeloid Leukemia
Primary: Count of Patients With Treatment-Emergent Adverse Events (Phase 1) — 6 Participants
AML
Primary: Complete Response Rate — 19 Participants
Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia
Primary: Percentage of Patients we Are Able to Test and Initiate Treatment Within a 21 Day Period — 21 Participants
Newly Diagnosed AML With FLT3 Activating Mutations
Primary: Clinical Response to Crenolanib With Standard Induction Chemotherapy — 26; 12; 38; 22 Participants